AUS
NZ
UK
CA
USA
IND
On July 27, 2026, Terence Rooney, Chief Medical Officer of Kymera Therapeutics Inc., received a substantial equity compensation package, as disclosed in a Securities and Exchange Commission filing. The award, comprising restricted stock units and stock options, aligns with executive compensation norms at the NASDAQ-listed biopharmaceutical firm specializing in targeted protein degradation therapies. This disclosure highlights management’s vested interest in shareholder value creation.
Key Points
- NASDAQ: KYMR
- Terence Rooney granted 38,000 restricted stock units and 76,000 stock options on July 27, 2026
- Stock options have an exercise price of $110.05 per share covering 76,000 shares
- RSUs vest annually over four years; stock options vest 25% after one year, then monthly over three years, contingent on continued employment
Overview of Kymera Therapeutics’ Executive Equity Compensation
The equity awards granted to Chief Medical Officer Terence Rooney on July 27, 2026, consist of 38,000 restricted stock units (RSUs) and 76,000 stock options. These awards reflect standard compensation practices for senior executives in the biopharmaceutical industry, emphasizing long-term management involvement in company performance and shareholder value enhancement.
The vesting conditions require Rooney’s continued employment at Kymera Therapeutics, ensuring alignment between executive incentives and sustained corporate success. This structure incentivizes retention and performance, as economic benefits from these equity awards depend on both tenure and stock appreciation.
Restricted Stock Units and Vesting Schedule
Rooney’s RSU grant includes 38,000 units, each representing a potential share of Kymera Therapeutics common stock upon vesting. These RSUs vest in four equal annual installments starting from the grant date of July 27, 2026, translating to approximately 9,500 shares vesting each year, contingent on Rooney’s continued employment.
This four-year vesting timeline is a common industry practice designed to promote long-term executive commitment and protect shareholder interests by preventing accelerated equity benefits upon premature departure.
Stock Options Details and Exercise Terms
In addition to RSUs, Rooney received 76,000 stock options on July 27, 2026, with an exercise price of $110.05 per share and a ten-year expiration through July 26, 2036. These options become valuable only if Kymera’s stock price exceeds the exercise price during this period.
The options vest 25% after one year (approximately 19,000 shares) and then vest monthly in equal installments over the following three years (about 1,583 shares per month), contingent upon Rooney’s ongoing employment. This vesting schedule further aligns Rooney’s incentives with the company’s long-term performance.
Ownership and Beneficial Interest
Following the July 27, 2026 transaction, Rooney beneficially owns 38,000 shares via RSUs and holds options for an additional 76,000 shares. The RSUs represent contingent ownership rights pending vesting, while the stock options confer the legal right to purchase shares at the specified exercise price.
These holdings demonstrate Rooney’s significant financial stake in Kymera Therapeutics’ future success, reinforcing alignment between his leadership role and shareholder interests.
Role and Responsibilities of Terence Rooney
As Chief Medical Officer, Rooney oversees Kymera Therapeutics’ clinical development and regulatory strategies, including trial design, regulatory filings, and medical safety. His senior management position requires disclosure of beneficial ownership changes under securities laws, reflecting his influence on the company’s drug development pipeline.
Rooney’s equity stake incentivizes his commitment to advancing Kymera’s therapeutic programs amid the inherent risks and regulatory challenges of biopharmaceutical development.
Transaction and Regulatory Filing Details
The equity grant transaction took place on July 27, 2026, and was reported to the SEC under Section 16(a) of the Securities Exchange Act of 1934. Rooney is the sole reporting individual, with no joint filings. The transaction codes confirm this was an equity award grant rather than a market purchase.
The acquisition price for both RSUs and options was $0, consistent with compensation grants rather than purchases. The filing was submitted by Bruce Jacobs as attorney-in-fact for Rooney on the transaction date.
Investor Implications and Shareholder Alignment
The 114,000 total shares underlying Rooney’s equity awards underscore Kymera Therapeutics’ focus on retaining key executive talent in a competitive biotech sector. Rooney’s role in clinical strategy makes this long-term incentive critical for sustaining leadership continuity and company growth.
For investors, such grants align management’s financial interests with shareholder value creation but may also lead to dilution as RSUs vest and options are exercised, impacting earnings per share and ownership percentages.
Industry Context and Executive Compensation Trends
Kymera’s equity compensation approach mirrors industry norms where RSUs and stock options form the backbone of senior executive pay. Biotech firms rely heavily on equity incentives to attract and retain executives with specialized expertise critical to drug development success.
Operating in the targeted protein degradation space, Kymera competes for top medical leadership talent, making such equity awards essential to advancing its pipeline and achieving regulatory milestones.
Employment Contingencies and Risk Factors
The vesting of Rooney’s equity awards depends on his continued employment at Kymera Therapeutics through each vesting date. Early termination would result in forfeiture of unvested shares unless accelerated vesting provisions apply, which the filing does not disclose.
Investors should recognize that the ultimate value Rooney realizes depends on stock price performance and his tenure, with changes in leadership or company strategy potentially affecting vesting outcomes and equity value.
